Monday, August 19, 2024 9:01:53 PM
Instead of issuing general OTC style complaint, just back-up what you say with citations of the financials and actual numbers to actually make and support your case, as supported by cited facts.
© 2024, by StockItOut
Recent QNTM News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/02/2026 12:30:03 PM
- Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied • GlobeNewswire Inc. • 04/02/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/01/2026 12:02:04 PM
- Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis • GlobeNewswire Inc. • 04/01/2026 12:02:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 11:50:09 AM
- Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis • GlobeNewswire Inc. • 03/30/2026 11:50:00 AM
- Quantum Biopharma Provides Corporate Update • GlobeNewswire Inc. • 03/27/2026 11:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/27/2026 12:10:03 PM
- Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status • GlobeNewswire Inc. • 03/27/2026 12:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/26/2026 12:00:10 PM
- Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis • GlobeNewswire Inc. • 03/26/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/23/2026 12:24:03 PM
- Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd • GlobeNewswire Inc. • 03/23/2026 12:24:00 PM
- Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering • GlobeNewswire Inc. • 03/20/2026 11:35:00 PM
- Quantum BioPharma Provides Corporate Update • GlobeNewswire Inc. • 03/11/2026 11:55:00 PM
- Quantum BioPharma Provides Corporate Update • GlobeNewswire Inc. • 03/10/2026 11:45:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/03/2026 02:19:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/23/2025 01:00:05 PM
- Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) • GlobeNewswire Inc. • 12/23/2025 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2025 09:23:02 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/22/2025 08:48:55 PM
- World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares • ACCESS Newswire • 12/22/2025 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2025 12:00:04 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 12/11/2025 03:14:49 PM
- Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update • Newsfile • 12/11/2025 01:00:00 AM
